{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:40:25Z","timestamp":1793720425810,"version":"4.6.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["2022.08921.PTDC"],"award-info":[{"award-number":["2022.08921.PTDC"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sk\u0142odowska-Curie grant","award":["Agreement No 847635"],"award-info":[{"award-number":["Agreement No 847635"]}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The hormone relaxin-2 has emerged as a promising player in regulating the physiology of the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1), this hormone elicits multiple physiological responses including vasodilation induction, reduction of inflammation and oxidative stress, and angiogenesis stimulation. The role of relaxin-2, or its recombinant human form known as serelaxin, has been investigated in preclinical and clinical studies as a potential therapy for cardiovascular diseases, especially heart failure, whose current therapy is still unoptimized. However, evidence from past clinical trials has been inconsistent and further research is needed to fully understand the potential applications of relaxin-2. This review provides an overview of serelaxin use in clinical trials and discusses future directions in the development of relaxin-2 mimetics, which may offer new therapeutic options for patients with heart failure.<\/jats:p>","DOI":"10.1007\/s00392-023-02305-1","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:01:50Z","timestamp":1695009710000},"page":"1137-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives"],"prefix":"10.1007","volume":"113","author":[{"given":"N\u00edsia","family":"Almeida-Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Bernd","family":"Dschietzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-436X","authenticated-orcid":false,"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"2305_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","volume":"487","author":"B Martin","year":"2019","unstructured":"Martin B, Romero G, Salama G (2019) Cardioprotective actions of relaxin. Mol Cell Endocrinol 487:45\u201353","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2305_CR2","doi-asserted-by":"publisher","first-page":"e12464","DOI":"10.1111\/micc.12464","volume":"26","author":"M Jelinic","year":"2019","unstructured":"Jelinic M et al (2019) From pregnancy to cardiovascular disease: lessons from relaxin-deficient animals to understand relaxin actions in the vascular system. Microcirculation 26(2):e12464","journal-title":"Microcirculation"},{"issue":"6","key":"2305_CR3","doi-asserted-by":"publisher","first-page":"R753","DOI":"10.1152\/ajpregu.00276.2017","volume":"314","author":"M Jelinic","year":"2018","unstructured":"Jelinic M et al (2018) Peptide hormone relaxin: from bench to bedside. Am J Physiol Regul Integr Comp Physiol 314(6):R753-r760","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"2305_CR4","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","volume":"301","author":"KP Conrad","year":"2011","unstructured":"Conrad KP (2011) Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 301(2):R267\u2013R275","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"10","key":"2305_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bph.13523","volume":"174","author":"M Sarwar","year":"2017","unstructured":"Sarwar M et al (2017) The actions of relaxin on the human cardiovascular system. Br J Pharmacol 174(10):933\u2013949","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2305_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.114.009472","volume":"67","author":"ML Halls","year":"2015","unstructured":"Halls ML et al (2015) International union of basic and clinical pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1\u20134, the receptors for relaxin family peptides. Pharmacol Rev 67(2):389\u2013440","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2305_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/ijms21020631","volume":"21","author":"L Jakubauskiene","year":"2020","unstructured":"Jakubauskiene L et al (2020) Relaxin positively influences ischemia-reperfusion injury in solid organ transplantation: a comprehensive review. Int J Mol Sci 21(2):631","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2305_CR8","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.7150\/thno.38640","volume":"10","author":"T Wilhelmi","year":"2020","unstructured":"Wilhelmi T et al (2020) Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. Theranostics 10(9):3905\u20133924","journal-title":"Theranostics"},{"issue":"1","key":"2305_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/0886022X.2022.2044351","volume":"44","author":"C Feiteng","year":"2022","unstructured":"Feiteng C et al (2022) Relaxin inhibits renal fibrosis and the epithelial-to-mesenchymal transition via the Wnt\/\u03b2-catenin signaling pathway. Ren Fail 44(1):513\u2013524","journal-title":"Ren Fail"},{"issue":"1","key":"2305_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2009.198","volume":"7","author":"XJ Du","year":"2010","unstructured":"Du XJ et al (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7(1):48\u201358","journal-title":"Nat Rev Cardiol"},{"key":"2305_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","volume":"487","author":"GR Brian Martin","year":"2019","unstructured":"Brian Martin GR (2019) Guy Salama Cardioprotective actions of relaxin. Mol Cell Endocrinol 487:45\u201353","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2305_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/01.RES.0000051884.27117.7E","volume":"92","author":"T Dschietzig","year":"2003","unstructured":"Dschietzig T et al (2003) Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1\/2 and nuclear factor-kappaB. Circ Res 92(1):32\u201340","journal-title":"Circ Res"},{"issue":"3","key":"2305_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/1566524019666191023121607","volume":"20","author":"RC Martins","year":"2020","unstructured":"Martins RC et al (2020) Relaxin and the cardiovascular system: from basic science to clinical practice. Curr Mol Med 20(3):167\u2013184","journal-title":"Curr Mol Med"},{"key":"2305_CR14","doi-asserted-by":"publisher","first-page":"114884","DOI":"10.1016\/j.bcp.2021.114884","volume":"197","author":"CS Samuel","year":"2022","unstructured":"Samuel CS, Bennett RG (2022) Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions. Biochem Pharmacol 197:114884","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2305_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"KF Adams Jr","year":"2005","unstructured":"Adams KF Jr et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209\u2013216","journal-title":"Am Heart J"},{"key":"2305_CR16","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2147\/TCRM.S340587","volume":"17","author":"T Lan","year":"2021","unstructured":"Lan T et al (2021) Mortality and readmission rates after heart failure: a systematic review and meta-analysis. Ther Clin Risk Manag 17:1307\u20131320","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2305_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/jcm12031020","volume":"12","author":"P Severino","year":"2023","unstructured":"Severino P et al (2023) Heart failure pharmacological management: gaps and current perspectives. J Clin Med 12(3):1020","journal-title":"J Clin Med"},{"issue":"5","key":"2305_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ejhf.1169","volume":"20","author":"R Ferrari","year":"2018","unstructured":"Ferrari R et al (2018) Acute heart failure: lessons learned, roads ahead. Eur J Heart Fail 20(5):842\u2013850","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2305_CR19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1096\/fj.01-0070com","volume":"15","author":"T Dschietzig","year":"2001","unstructured":"Dschietzig T et al (2001) The pregnancy hormone relaxin is a player in human heart failure. Faseb j 15(12):2187\u20132195","journal-title":"Faseb j"},{"key":"2305_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1749-6632.2008.03819.x","volume":"1160","author":"T Dschietzig","year":"2009","unstructured":"Dschietzig T et al (2009) First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Ann N Y Acad Sci 1160:387\u2013392","journal-title":"Ann N Y Acad Sci"},{"issue":"9673","key":"2305_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","volume":"373","author":"JR Teerlink","year":"2009","unstructured":"Teerlink JR et al (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373(9673):1429\u20131439","journal-title":"Lancet"},{"issue":"10","key":"2305_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/eurjhf\/hfq132","volume":"12","author":"M Metra","year":"2010","unstructured":"Metra M et al (2010) Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 12(10):1130\u20131139","journal-title":"Eur J Heart Fail"},{"key":"2305_CR23","unstructured":"Novartis Pharmaceuticals. Pharmacokinetics & safety of serelaxin on top of standard of care therapy in pediatric patients with acute heart failure (RELAX-PEDS-PK). Accessed 5 Jan 2023"},{"issue":"9860","key":"2305_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink JR et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381(9860):29\u201339","journal-title":"Lancet"},{"issue":"16","key":"2305_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/eurheartj\/eht497","volume":"35","author":"G Filippatos","year":"2013","unstructured":"Filippatos G et al (2013) Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 35(16):1041\u20131050","journal-title":"Eur Heart J"},{"issue":"2","key":"2305_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","volume":"61","author":"M Metra","year":"2013","unstructured":"Metra M et al (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program. J Am Coll Cardiol 61(2):196\u2013206","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2305_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"M Metra","year":"2019","unstructured":"Metra M et al (2019) Effects of serelaxin in patients with acute heart failure. N Engl J Med 381(8):716\u2013726","journal-title":"N Engl J Med"},{"issue":"6","key":"2305_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ejhf.830","volume":"19","author":"JR Teerlink","year":"2017","unstructured":"Teerlink JR et al (2017) Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail 19(6):800\u2013809","journal-title":"Eur J Heart Fail"},{"key":"2305_CR29","unstructured":"Novartis Pharmaceuticals. Efficacy, safety and tolerability of sexelaxin when added to standard therapy in AHF (RELAX-AHF-ASIA). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02007720. Accessed 13 Jun 2023"},{"issue":"1","key":"2305_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cardfail.2016.10.016","volume":"23","author":"N Sato","year":"2017","unstructured":"Sato N et al (2017) Evaluating the efficacy, safety, and tolerability of serelaxin when added to standard therapy in Asian patients with acute heart failure: design and rationale of RELAX-AHF-ASIA trial. J Card Fail 23(1):63\u201371","journal-title":"J Card Fail"},{"issue":"2","key":"2305_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ejhf.1692","volume":"22","author":"JR Teerlink","year":"2020","unstructured":"Teerlink JR et al (2020) Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. Eur J Heart Fail 22(2):315\u2013329","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2305_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cardfail.2018.11.007","volume":"24","author":"N Sato","year":"2018","unstructured":"Sato N, Lam CS, Teerlink JR, Greenberg BH, Tsutsui H, Oh B, Zhang J, Hua TA, Wang XL, Ge J (2018) The efficacy, safety, and tolerability of additional serelaxin administration to standard therapy in Asian patients with acute heart failure: the RELAX-AHF-ASIA trial. J Cardiac Fail 24(11):812","journal-title":"J Cardiac Fail"},{"issue":"3","key":"2305_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ejhf.1368","volume":"21","author":"AP Maggioni","year":"2019","unstructured":"Maggioni AP et al (2019) Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study RELAX-AHF-EU. Eur J Heart Fail 21(3):322\u2013333","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2305_CR34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.106.623199","volume":"114","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M et al (2006) Navigating the crossroads of coronary artery disease and heart failure. Circulation 114(11):1202\u20131213","journal-title":"Circulation"},{"issue":"3","key":"2305_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10741-005-6127-6","volume":"9","author":"GC Fonarow","year":"2004","unstructured":"Fonarow GC, Corday E, Committee ASA (2004) Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 9(3):179\u2013185","journal-title":"Heart Fail Rev"},{"issue":"6","key":"2305_CR36","first-page":"609","volume":"113","author":"J Valle Raleigh","year":"2017","unstructured":"Valle Raleigh J et al (2017) Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res 113(6):609\u2013619","journal-title":"Cardiovasc Res"},{"issue":"11","key":"2305_CR37","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1096\/fj.04-3664fje","volume":"19","author":"AM Perna","year":"2005","unstructured":"Perna AM et al (2005) Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. Faseb j 19(11):1525\u20131527","journal-title":"Faseb j"},{"issue":"1","key":"2305_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/cvr\/cvz345","volume":"117","author":"D Corcoran","year":"2021","unstructured":"Corcoran D et al (2021) Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovasc Res 117(1):320\u2013329","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2305_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/01.fjc.0000245404.20922.9f","volume":"48","author":"R Jagathesan","year":"2006","unstructured":"Jagathesan R et al (2006) Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: a substudy of the persantine in stable angina (PISA) study. J Cardiovasc Pharmacol 48(3):110\u2013116","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2305_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/01.CIR.57.4.732","volume":"57","author":"T Mann","year":"1978","unstructured":"Mann T et al (1978) Effect of nitroprusside on regional myocardial blood flow in coronary artery disease: results in 25 patients and comparison with nitroglycerin. Circulation 57(4):732\u20138","journal-title":"Circulation"},{"issue":"4","key":"2305_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","volume":"14","author":"SL Teichman","year":"2009","unstructured":"Teichman SL et al (2009) Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 14(4):321\u2013329","journal-title":"Heart Fail Rev"},{"issue":"18","key":"2305_CR42","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","volume":"296","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M et al (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18):2217\u20132226","journal-title":"JAMA"},{"issue":"2","key":"2305_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1161\/CIRCOUTCOMES.113.000418","volume":"7","author":"TS Wang","year":"2014","unstructured":"Wang TS et al (2014) Representativeness of RELAX-AHF clinical trial population in acute heart failure. Circ Cardiovasc Qual Outcomes 7(2):259\u2013268","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"2305_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00392-015-0854-z","volume":"104","author":"O Miro","year":"2015","unstructured":"Miro O et al (2015) How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry. Clin Res Cardiol 104(10):850\u2013860","journal-title":"Clin Res Cardiol"},{"issue":"40","key":"2305_CR45","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1093\/eurheartj\/eht380","volume":"34","author":"RE Schmieder","year":"2013","unstructured":"Schmieder RE (2013) RELAX-AHF: consistency across subgroups and new hypotheses generated. Eur Heart J 34(40):3100\u20133101","journal-title":"Eur Heart J"},{"issue":"9","key":"2305_CR46","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.1780","volume":"22","author":"BA Davison","year":"2020","unstructured":"Davison BA et al (2020) Mega-trials in heart failure: effects of dilution in examination of new therapies. Eur J Heart Fail 22(9):1698\u20131707","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2305_CR47","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/ejhf.1574","volume":"21","author":"J Hall\u00e9n","year":"2019","unstructured":"Hall\u00e9n J et al (2019) Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. Eur J Heart Fail 21(12):1661\u20131662","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2305_CR48","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.drudis.2020.04.014","volume":"25","author":"D Bani","year":"2020","unstructured":"Bani D (2020) Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. Drug Discov Today 25(7):1239\u20131244","journal-title":"Drug Discov Today"},{"issue":"3","key":"2305_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.amjcard.2017.04.056","volume":"120","author":"PA McCullough","year":"2017","unstructured":"McCullough PA (2017) How trialists and pharmaceutical sponsors have failed us by thinking that acute heart failure is a 48-hour illness. Am J Cardiol 120(3):505\u2013508","journal-title":"Am J Cardiol"},{"issue":"20","key":"2305_CR50","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer M et al (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 376(20):1956\u20131964","journal-title":"N Engl J Med"},{"issue":"8","key":"2305_CR51","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.cardfail.2016.06.051","volume":"22","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR et al (2016) RELAX-REPEAT: a multicenter, prospective, randomized, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure. J Cardiac Failure 22(8):S14\u2013S15","journal-title":"J Cardiac Failure"},{"key":"2305_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16055","author":"P Verdino","year":"2023","unstructured":"Verdino P et al (2023) Development of a long-acting relaxin analog, LY3540378, for treatment of chronic heart failure. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.16055","journal-title":"Br J Pharmacol"},{"key":"2305_CR53","unstructured":"A study of LY3540378 in participants with worsening chronic heart failure with preserved ejection fraction (HFpEF). Accessed 5 Feb 2023"},{"issue":"1","key":"2305_CR54","doi-asserted-by":"publisher","first-page":"20435","DOI":"10.1038\/s41598-022-24716-2","volume":"12","author":"S Illiano","year":"2022","unstructured":"Illiano S et al (2022) Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models. Sci Rep 12(1):20435","journal-title":"Sci Rep"},{"issue":"5","key":"2305_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejhf.2853","volume":"25","author":"SJ Pocock","year":"2023","unstructured":"Pocock SJ et al (2023) The win ratio method in heart failure trials: lessons learnt from EMPULSE. Eur J Heart Fail 25(5):632\u2013641","journal-title":"Eur J Heart Fail"},{"key":"2305_CR56","first-page":"1237","volume":"79","author":"N Sato","year":"2015","unstructured":"Sato N, Takahashi W, Hirayama A, Ajioka M, Takahashi N, Okishige K, Wang X, Maki A, Maruyama H, Ebinger U, Yamaguchi M, Pang Y (2015) Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure. Off J Jpn Circ Soc 79:1237\u20131247","journal-title":"Off J Jpn Circ Soc"},{"issue":"10","key":"2305_CR57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2015.51.10.2386731","volume":"51","author":"VA Kumar","year":"2015","unstructured":"Kumar VA et al (2015) Targeted biological therapies reach the heart: the case of serelaxin for heart failure. Drugs Today 51(10):591\u2013597","journal-title":"Drugs Today"},{"key":"2305_CR58","unstructured":"Study of the effect of serelaxin on high-sensitivity cardiac troponin I (Hs-cTnI) release in patients with chronic heart failure (RELAX-Cardio). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625922?cond=NCT02625922&draw=2&rank=1. Accessed 5 Jan 2023"},{"issue":"11","key":"2305_CR59","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1164\/rccm.201509-1865OC","volume":"194","author":"J Tan","year":"2016","unstructured":"Tan J et al (2016) Expression of RXFP1 is decreased in idiopathic pulmonary fibrosis: implications for relaxin-based therapies. Am J Respir Crit Care Med 194(11):1392\u20131402","journal-title":"Am J Respir Crit Care Med"},{"key":"2305_CR60","doi-asserted-by":"publisher","first-page":"114370","DOI":"10.1016\/j.biopha.2023.114370","volume":"160","author":"F Alam","year":"2023","unstructured":"Alam F et al (2023) The single-chain relaxin mimetic, B7\u201333, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother 160:114370","journal-title":"Biomed Pharmacother"},{"key":"2305_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mce.2018.12.013","volume":"487","author":"HH Ng","year":"2019","unstructured":"Ng HH, Esteban-Lopez M, Agoulnik AI (2019) Targeting the relaxin\/insulin-like family peptide receptor 1 and 2 with small molecule compounds. Mol Cell Endocrinol 487:40\u201344","journal-title":"Mol Cell Endocrinol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02305-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:18:48Z","timestamp":1721830728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02305-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02305-1","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TBD is CEO of Relaxera, a pharmaceutical company developing relaxin-2 for transplantation medicine. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}